Treatment of benign prostatic hyperplasia in hypertensive men - PubMed
Review
Treatment of benign prostatic hyperplasia in hypertensive men
William B White et al. J Clin Hypertens (Greenwich). 2005 Apr.
Abstract
As the proportion of the US population over the age of 65 continues to rise, it is likely that the number of individuals with concomitant benign prostatic hyperplasia and hypertension will also increase. To reduce morbidity and mortality, it is important to treat patients with hypertension optimally. Evidence from outcome trials suggests that alpha1 blockers should not be used as first-line antihypertensive therapy. Although some clinicians previously recommended alpha1 blocker monotherapy for patients with both hypertension and benign prostatic hyperplasia, the most recent American Urologic Association and Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure guidelines recommend independent treatment with the most appropriate pharmacologic agents for each condition. When treating patients with benign prostatic hyperplasia, clinicians should be aware of the potential impacts that alpha1 blockers may have on blood pressure and potential adverse events in patients who are normotensive as well as in patients with treated hypertension.
Similar articles
-
Tewari A, Narayan P. Tewari A, et al. Urology. 1999 Mar;53(3 Suppl 3a):14-20; discussion 41-2. doi: 10.1016/s0090-4295(98)00534-2. Urology. 1999. PMID: 10094096 Review.
-
Lowe FC, Olson PJ, Padley RJ. Lowe FC, et al. Urology. 1999 Jul;54(1):81-5. doi: 10.1016/s0090-4295(99)00057-6. Urology. 1999. PMID: 10414731 Clinical Trial.
-
Cost-effective monotherapy of concomitant benign prostatic hyperplasia and hypertension.
Altwein JE. Altwein JE. Br J Hosp Med. 1997 Dec 10;58(11):592-4. Br J Hosp Med. 1997. PMID: 10193480 Review.
Cited by
-
Alpha1-adrenergic blockers: current usage considerations.
Sica DA. Sica DA. J Clin Hypertens (Greenwich). 2005 Dec;7(12):757-62. doi: 10.1111/j.1524-6175.2005.05300.x. J Clin Hypertens (Greenwich). 2005. PMID: 16330901 Free PMC article. Review.
-
Rył A, Rotter I, Słojewski M, Jędrzychowska A, Marcinowska Z, Grabowska M, Laszczyńska M. Rył A, et al. Int J Environ Res Public Health. 2015 Mar 19;12(3):3327-42. doi: 10.3390/ijerph120303327. Int J Environ Res Public Health. 2015. PMID: 25809513 Free PMC article.
-
Kitapçı MT, Karakuş O, İşli F, Aksoy M, Güvel MC, Uluoğlu C. Kitapçı MT, et al. Anatol J Cardiol. 2023 Jun;27(6):328-338. doi: 10.14744/AnatolJCardiol.2023.2618. Anatol J Cardiol. 2023. PMID: 37257006 Free PMC article.
References
-
- Boyle P, Napalkov P. The epidemiology of benign prostatic hyperplasia and observations on concomitant hypertension. Scand J Urol Nephro Suppl. 1995; 168: 7–12. - PubMed
-
- Ng AV, Callister R, Johnson DG, et al. Age and gender influence muscle sympathetic nerve activity at rest in healthy humans. Hypertension. 1993; 21:498–503. - PubMed
-
- Kaplan SA, Kaplan NM. Alpha‐blockade: monotherapy for hypertension and benign prostatic hyperplasia. Urology. 1996; 48: 541–550. - PubMed
-
- Schulman CC, Cortvriend J, Jonas U, et al., on behalf of the European Tamsulosin Study Group. Tamsulosin, the first prostate‐selective α1A‐adrenergic antagonist. Analysis of a multinational, multicentre, open‐label study assessing the long‐term efficacy and safety in patients with benign prostatic obstruction (symptomatic BPH). Eur Urol. 1996;29:145–154. - PubMed
-
- Chapple CR, Aubry ML, James S, et al. Characterization of human prostatic adrenoceptors using pharmacology receptor binding and localization. Br J Urol. 1989; 63: 487–496. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials